These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
324 related articles for article (PubMed ID: 34036223)
1. Impact of ALK Inhibitors in Patients With Takeyasu Y; Okuma HS; Kojima Y; Nishikawa T; Tanioka M; Sudo K; Shimoi T; Noguchi E; Arakawa A; Mori T; Sunami K; Kubo T; Kohno T; Akihiko Y; Yamamoto N; Yonemori K JCO Precis Oncol; 2021; 5():. PubMed ID: 34036223 [TBL] [Abstract][Full Text] [Related]
2. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study. Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430 [TBL] [Abstract][Full Text] [Related]
3. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib. Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort. Bedas A; Peled N; Maimon Rabinovich N; Mishaeli M; Shochat T; Zer A; Rotem O; Allen AM; Bar J; Dudnik E; Oncol Res Treat; 2019; 42(5):275-282. PubMed ID: 30955009 [TBL] [Abstract][Full Text] [Related]
5. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review. Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785 [TBL] [Abstract][Full Text] [Related]
6. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing. Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186 [TBL] [Abstract][Full Text] [Related]
7. Clinical outcome, long-term survival and tolerability of sequential therapy of first-line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China. Zou Z; Hao X; Zhang C; Li H; Dong G; Peng Y; Ma K; Guo Y; Shan L; Zhang Y; Liang L; Gu Y; Xing P; Li J Thorac Cancer; 2022 Jan; 13(1):107-116. PubMed ID: 34851035 [TBL] [Abstract][Full Text] [Related]
8. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538 [TBL] [Abstract][Full Text] [Related]
9. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Zhou C; Kim SW; Reungwetwattana T; Zhou J; Zhang Y; He J; Yang JJ; Cheng Y; Lee SH; Bu L; Xu T; Yang L; Wang C; Liu T; Morcos PN; Lu Y; Zhang L Lancet Respir Med; 2019 May; 7(5):437-446. PubMed ID: 30981696 [TBL] [Abstract][Full Text] [Related]
10. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Gadgeel S; Peters S; Mok T; Shaw AT; Kim DW; Ou SI; Pérol M; Wrona A; Novello S; Rosell R; Zeaiter A; Liu T; Nüesch E; Balas B; Camidge DR Ann Oncol; 2018 Nov; 29(11):2214-2222. PubMed ID: 30215676 [TBL] [Abstract][Full Text] [Related]
11. Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report. Honda K; Kadowaki S; Kato K; Hanai N; Hasegawa Y; Yatabe Y; Muro K Invest New Drugs; 2019 Aug; 37(4):791-795. PubMed ID: 30790150 [TBL] [Abstract][Full Text] [Related]
12. Exposure-Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non-Small Cell Lung Cancer Patients. Groenland SL; Geel DR; Janssen JM; de Vries N; Rosing H; Beijnen JH; Burgers JA; Smit EF; Huitema ADR; Steeghs N Clin Pharmacol Ther; 2021 Feb; 109(2):394-402. PubMed ID: 32686074 [TBL] [Abstract][Full Text] [Related]
13. ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study. Wang M; Slatter S; Sussell J; Lin CW; Ogale S; Datta D; Butte AJ; Bazhenova L; Rudrapatna VA Target Oncol; 2023 Jul; 18(4):571-583. PubMed ID: 37341856 [TBL] [Abstract][Full Text] [Related]
14. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer. Gadgeel SM Future Oncol; 2018 Aug; 14(18):1875-1882. PubMed ID: 29536761 [TBL] [Abstract][Full Text] [Related]
15. Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non-Small-Cell Lung Cancer: A Retrospective Analysis. Asao T; Fujiwara Y; Itahashi K; Kitahara S; Goto Y; Horinouchi H; Kanda S; Nokihara H; Yamamoto N; Takahashi K; Ohe Y Clin Lung Cancer; 2017 Jul; 18(4):e251-e258. PubMed ID: 28065466 [TBL] [Abstract][Full Text] [Related]
17. Crizotinib for recurring non-small-cell lung cancer with EML4-ALK fusion genes previously treated with alectinib: A phase II trial. Harada D; Isozaki H; Kozuki T; Yokoyama T; Yoshioka H; Bessho A; Hosokawa S; Takata I; Takigawa N; Hotta K; Kiura K; Thorac Cancer; 2021 Mar; 12(5):643-649. PubMed ID: 33470536 [TBL] [Abstract][Full Text] [Related]
18. Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study. Ito K; Yamanaka T; Hayashi H; Hattori Y; Nishino K; Kobayashi H; Oya Y; Yokoyama T; Seto T; Azuma K; Fukui T; Kozuki T; Nakamura A; Tanaka K; Hirano K; Yokoi T; Daga H; Sakata S; Fujimoto D; Mori M; Maeno K; Aoki T; Tamura A; Miura S; Watanabe S; Akamatsu H; Hataji O; Suzuki K; Hontsu S; Azuma K; Bessho A; Kubo A; Okuno M; Nakagawa K; Yamamoto N Eur J Cancer; 2021 Mar; 145():183-193. PubMed ID: 33486442 [TBL] [Abstract][Full Text] [Related]
19. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. Peters S; Camidge DR; Shaw AT; Gadgeel S; Ahn JS; Kim DW; Ou SI; Pérol M; Dziadziuszko R; Rosell R; Zeaiter A; Mitry E; Golding S; Balas B; Noe J; Morcos PN; Mok T; N Engl J Med; 2017 Aug; 377(9):829-838. PubMed ID: 28586279 [TBL] [Abstract][Full Text] [Related]
20. Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC. Arnaoutakis K; Wan Y; Elliott J; Young M; Yin Y; Leventakos K; Lin HM; Dimou A Adv Ther; 2024 Aug; 41(8):3217-3231. PubMed ID: 38916812 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]